BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price hoisted by JMP Securities from $10.00 to $11.00 in a research note issued to investors on Friday, The Fly reports. JMP Securities currently has an outperform rating on the biotechnology company’s stock.
A number of other analysts have also recently commented on BCRX. Zacks Investment Research cut BioCryst Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, May 22nd. Piper Sandler reiterated a buy rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, June 8th. BidaskClub lowered shares of BioCryst Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, June 2nd. Barclays upgraded shares of BioCryst Pharmaceuticals from an equal weight rating to an overweight rating and raised their target price for the stock from $4.00 to $7.00 in a research report on Tuesday, May 5th. Finally, BTIG Research initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 16th. They issued a neutral rating for the company. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. BioCryst Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $7.64.
BCRX stock opened at $4.98 on Friday. The company has a debt-to-equity ratio of 11.03, a current ratio of 1.35 and a quick ratio of 1.35. The company’s 50 day simple moving average is $4.68 and its 200-day simple moving average is $3.34. BioCryst Pharmaceuticals has a 12 month low of $1.38 and a 12 month high of $6.29. The firm has a market capitalization of $852.02 million, a PE ratio of -5.30 and a beta of 2.78.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.24). The firm had revenue of $4.82 million for the quarter, compared to analyst estimates of $2.71 million. BioCryst Pharmaceuticals had a negative return on equity of 4,223.68% and a negative net margin of 241.66%. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.95 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in BCRX. BlackRock Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 10.3% during the 1st quarter. BlackRock Inc. now owns 13,395,617 shares of the biotechnology company’s stock worth $26,790,000 after buying an additional 1,245,406 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of BioCryst Pharmaceuticals by 157.1% in the 4th quarter. Point72 Asset Management L.P. now owns 8,382,900 shares of the biotechnology company’s stock worth $28,921,000 after purchasing an additional 5,122,900 shares during the period. State Street Corp lifted its stake in shares of BioCryst Pharmaceuticals by 4.6% in the 1st quarter. State Street Corp now owns 5,746,052 shares of the biotechnology company’s stock valued at $11,492,000 after purchasing an additional 253,109 shares in the last quarter. UBS Group AG grew its holdings in shares of BioCryst Pharmaceuticals by 80.7% during the 4th quarter. UBS Group AG now owns 5,488,287 shares of the biotechnology company’s stock worth $18,935,000 after purchasing an additional 2,450,478 shares during the period. Finally, FMR LLC raised its holdings in BioCryst Pharmaceuticals by 15.9% in the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after buying an additional 475,989 shares during the period. Institutional investors own 79.53% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Read More: Why is Cost of Capital Important?
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.